Committed to improving patients’ lives

At ACADIA (NASDAQ: ACAD), we share a passion for improving the lives of patients with neurological and related central nervous system (CNS) disorders.

Our pipeline of product candidates is led by NUPLAZIDTM (pimavanserin), which, if approved, will establish a new and distinctly different pharmacological approach to treating psychosis and be the only drug approved in the United States for the treatment of psychosis associated with Parkinson’s disease. We also are developing pimavanserin for Alzheimer’s disease psychosis and schizophrenia—additional areas with severe unmet medical needs. In addition, we have collaborative clinical-stage programs for chronic pain and glaucoma.

Our vision is to become a leading biopharmaceutical company dedicated to developing and commercializing innovative therapies in the CNS area. Our history is rooted in science and strong leadership in CNS research. We have set ourselves apart by transforming our novel discoveries into important drug candidates that may make a meaningful impact on the lives of patients and the family members who care for them every day.

Company Information

Publication Spotlight

Parkinson’s disease psychosis, which includes hallucinations and delusions, is frequent and debilitating in people with Parkinson’s disease. We aimed to assess safety and efficacy of pimavanserin, a selective serotonin 5-HT2A inverse agonist, in this population.